Nanolattix Chairman Qu Zhican Invited to Attend 3rd Radiopharmaceutical Development Summit, Collaborates to Shape RDC Innovation Landscape
Release time:
2026-03-23
On March 19, 2026, the highly anticipated 3rd Radiopharmaceutical Development Summit (RDS 2026) was grandly held in Shanghai. As a premier event in the radiopharmaceutical field, the summit brought together top experts, scholars, and industry leaders from around the world in radiopharmaceutical development. Qu Zhican, Chairman of Nanolattix, was invited to attend and engage in discussions with global experts on innovative developments in radiopharmaceuticals.
During the summit's core agenda, Dr. Qu Zhican engaged in in-depth dialogues with fellow radiopharmaceutical experts on hot topics such as "Is the radiopharmaceutical track becoming crowded?" and "How to achieve differentiated positioning?" She also delivered a keynote speech, systematically elaborating on Nanolattix's innovative experience and strategic layout in the field of "RDC + ADC synergistic development." She showcased the unique advantages and innovative strength of Nanolattix's BioLattix biotechnology platform, which garnered extensive attention and high recognition from attending experts.
Notably, Markus Reschke, Vice President of Radioligand Therapy at global radiopharmaceutical giant Novartis, also attended the conference and delivered a keynote speech titled "Next-Generation RLTs - Challenges and Opportunities," providing an in-depth analysis of the technological frontiers and development opportunities for next-generation radioligand therapies (RLTs).
This summit not only provided Nanolattix with an international stage to showcase its innovative strength but also built an important bridge to deepen exchanges and cooperation in the global radiopharmaceutical field. Moving forward, Nanolattix will continue to increase R&D investment, deepen strategic collaborations with global partners, and accelerate the development of radiopharmaceutical products with greater clinical value to benefit patients, contributing "Nanolattix Strength" to global innovation in radiopharmaceutical development.
Tag:
recommend News
Share
